Morning Overview on MSN
A daily multivitamin just slowed all five epigenetic aging clocks in a randomized trial — the people who started biologically older showed the biggest benefit
A two-year randomized trial found that a daily multivitamin slowed biological aging across all five epigenetic clocks tested ...
GlobalData on MSN
Abivax’s obefazimod met primary endpoint in Phase III ABTECT trial
The results showed obefazimod met the FDA primary endpoint of placebo-adjusted clinical remission at week 44.
Peer-reviewed randomized controlled trial of 427 adults found that after completing Noom’s 16-week program, members continued ...
At least 12 of my colleagues boarded planes to the American Society of Clinical Oncology conference in Chicago last week to hear Charles Swanton of the Francis Crick Institute in London share results ...
Previous clinical trials suggested that ultra-thin strut biodegradable polymer sirolimus-eluting stent (BP-SES) may be ...
Primary analyses showed no significant differences between the semaglutide and placebo groups in laboratory measures of ...
Morning Overview on MSN
A daily multivitamin slowed all five epigenetic aging clocks in a randomized trial — people who started biologically older saw the biggest benefit
A standard daily multivitamin, the kind sold at every pharmacy for roughly a dime a dose, slowed biological aging across ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results